Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies

作     者：Zhenan Deng Meiling Jin Changxing Ou Wei Jiang Jianping Zhao Xiaoxia Liu Shenghua Sun Huaping Tang Bei He Shaoxi Cai Ping Chen Penghui Wu Yujing Liu Jian Kang Yunhui Zhang Mao Huang Jinfu Xu Kewu Huang Qiang Li Xiangyan Zhang Xiuhua Fu Changzheng Wang Huahao Shen Lei Zhu Guochao Shi Zhongmin Qiu Zhongguang Wen Xiaoyang Wei Wei Gu Chunhua Wei Guangfa Wang Ping Chen Lixin Xie Jiangtao Lin Yuling Tang Zhihai Han Kian Fan Chung Qingling Zhang Nanshan Zhong C-BIOPRED Consortium 

作者机构：Pulmonary and Critical Care MedicineGuangzhou Institute of Respiratory HealthNational Clinical Research Center for Respiratory DiseaseNational Center for Respiratory MedicineState Key Laboratory of Respiratory DiseasesThe First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouGuangdong 510120China Department of Respiratory MedicineZhongshan HospitalShanghai 200433China Guangzhou Medical UniversityGuangzhouGuangdong 510180China AstraZenecaShanghai 200085China Department of Respiratory MedicineTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhanHubei 430030China Department of Respiratory MedicineBeijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of Respiratory MedicineThe Third Xiangya Hospital of Central South UniversityChangshaHunan 410013China Department of Respiratory MedicineQingdao Municipal HospitalQingdaoShandong 266001China Department of Respiratory MedicinePeking University Third HospitalBeijing 100191China Department of Respiratory MedicineNanfang Hospital of Southern Medical UniversityGuangzhouGuangdong 510515China Department of Respiratory MedicineGeneral Hospital of Northern Theater CommandShenyangLiaoning 110016China Department of Respiratory MedicineThe First Hospital of China Medical UniversityShenyangLiaoning 110001China Department of Respiratory MedicineThe First people’s Hospital of Yunnan ProvinceKunmingYunnan 363880China Department of Respiratory MedicineThe First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China Department of Respiratory MedicineShanghai Pulmonary HospitalShanghai 200433China Department of Respiratory MedicineBeijing Chao-Yang HospitalBeijing 100020China Department of Respiratory MedicineShanghai General HospitalShanghai 200080China Department of Respiratory MedicineGuizhou Province People’s HospitalGuiyangGuizhou 550002China Department of Respiratory MedicineThe Affiliated Hospital of Inner Mongolia Medical UniversityHuhhotInner Mongolia 010050China Department of Respiratory MedicineThe Third Affiliated Hospital of Chongqing Medical UniversityChongqing 401120China Department of Respiratory MedicineThe Second Affiliated hospital of Zhejiang University School of MedicineHangzhouZhejiang 310003China Department of Respiratory MedicineRuijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025China Department of Pulmonary and Critical Care MedicineTongji HospitalSchool of MedicineTongji UniversityShanghai 200065China Department of Respiratory MedicineThe First Affiliated Hospital of PLA General HospitalBeijing 100048China Department of Respiratory and Critical Care MedicineThe Eighth Medical Center of PLA General HospitalBeijing 100048China Department of RespiratoryNanjing First HospitalNanjing Medical UniversityNanjingJiangsu 210029China Department of Respiratory MedicineWeifang Weien HospitalWeifangShandong 261045China Department of Respiratory MedicinePeking University First HospitalBeijing 100034China Department of Respiratory MedicineThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China College of Pulmonary and Critical Care MedicineChinese PLA General HospitalBeijing 100853China Department of Respiratory MedicineChina-Japan Friendship HospitalBeijing 100029China Department of Respiratory MedicineThe First Hospital of ChangshaChangshaHunan 410005China Deparment of Pulmonary and Critical Care MedicineThe Sixth Medical Center of PLA General HospitalBeijing 100048China National Heart and Lung InstituteImperial College LondonLondon SW3UK Royal Brompton and Harefield NHS Foundation TrustLondon SW3UK 不详 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第2期

页      面：230-232页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：supported by grants from AstraZeneca China and the National Natural Science Foundation of China(No.82070026). 

主　　题：asthma therapies impairment 

摘      要：To the Editor:Patients with severe persistent asthma experience greater morbidity with more impairment in quality of life despite higher use of health care resources and being treated with existing asthma treatments such as inhaled corticosteroids and b-agonists,and sometimes oral corticosteroid(OCS)therapy.Type-2(T2)high asthma has been identified as a phenotype that responds to targeted T2 biologic therapies such as anti-IgE,anti-interleukin(IL)5,or anti-IL5Ra and anti-IL4Ra monoclonal antibodies,which are currently available in Europe and North America,and are currently introduced in the rest of the world.[1]